About 4SC AG

Company Description

4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.
4SC's current product pipeline includes two programs in clinical development: resminostat and domatinostat.
4SC's goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.

Year founded

1997

Served area

Germany

Headcount

46

Headquarters

Fraunhoferstraße 22, 82152 Planegg-Martinsried – Germany

Shareholder information

Shares outstanding

10,114,009

IPO

Dec. 15, 2005

Designated Sponsor(s)

Stifel Europe Bank AG

Stock exchange(s)

Frankfurt Stock Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.